The expression research of miR-210 in the elderly patients with COPD combined with ischemic stroke.

OBJECTIVE: We conduct this study to investigate the expression level of miR-210 in elderly patients with COPD combined with ischemic stroke and analyzed its application value as a sensitive diagnostic indicator. PATIENTS AND METHODS: 50 cases of elderly patients with COPD combined with ischemic stroke were selected as group A, 50 cases of elderly patients with COPD were selected as group B, 50 cases of elderly patients with ischemic stroke were selected as group C, and 50 cases of healthy volunteers as group D. Real-time PCR assay for quantification was used to detect the expression level of miR-210 in peripheral blood and receiver operating curve (ROC) was used to analyze the diagnostic sensitivity and accuracy. RESULTS: MiR-210 level of group A was the lowest, followed by group B and group C; group D had the highest levels. The difference was statistically significant (p<0.05). MiR-210 levels decreased with an increasing decline degree of lung function and the difference was statistically significant (p<0.05). After miR-210 diagnosis, COPD sensitivity was 85.6%, the specificity was 72.6%, accuracy (AUC) was 0.821, and 95% CI 0.632-0.924. CONCLUSIONS: The down-regulation of MiR-210 expression in the COPD combined with ischemic stroke can be regarded as a sensitive index in diagnosis of COPD and ischemic stroke.

Comparison of EGFR mutation rates in lung adenocarcinoma tissue and pleural effusion samples.

The goal of the current study was to investigate the differences in epidermal growth factor receptor (EGFR) mutation rates in tumor tissue and pleural effusion specimens from patients with lung adenocarcinoma. PCR amplification and gene sequencing were used to detect EGFR mutations in exons 18, 19, 20, and 21 in tumor tissue and pleural effusion samples from 50 patients with advanced lung adenocarcinoma. The EGFR mutation rate was 34.0% in tissue samples from patients with advanced lung adenocarcinoma. There were 11 cases with exon 19 mutations and 6 cases with exon 21 mutations. The EGFR mutation rate was 30.0% in pleural effusion specimens, including 10 cases with exon 19 mutation and 5 cases with exon 21 mutations. Although the tissue samples had a slightly higher mutation rate compared to the pleural effusion samples, the difference was not statistically significant. These results indicate that the EGFR mutation rate detected in pleural effusion specimens from patients with advanced lung adenocarcinoma is similar to that detected in tumor tissue samples. Therefore, pleural effusion specimens can potentially be used for EGFR mutation detection in advanced lung adenocarcinoma.